Objective: In HBeAg-negative patients who constitute most of the hepatitis B patients in our country, treatment decision is made according to biopsy result. Guidelines do not require biopsy in some patient groups and suggest the treatment decision with HBV DNA and alanine aminotransferase (ALT) level. Non-invasive fibrosis measurement tests can also be used to assess liver fibrosis status. In our study, we aimed to investigate fibrosis measurement tests' predictability of liver biopsy result which is an invasive procedure and to evaluate our patients in terms of guidelines and national treatment justification criteria. Methods: HBeAg-negative 25 patients who had undergone liver biopsy in our clinic were investigated retrospectively. Patients' demographic features, liver biopsy results, HBV DNA levels and treatment decisions were recorded. AST to Platelet Ratio Index (APRI) and Fibrosis-4 (FIB4) scores were calculated. The correlation between APRI and FIB4 scores and biopsy results was investigated. Patients whom treatment could not be started were evaluated for eligibility according to guidelines. Results: With the biopsy results, the treatment was started in 15 patients while 10 (40%) of the patients could not be treated according to the valid national reimbursement regulations. Six of these 10 patients were the patients with high HBV DNA and ALT levels. APRI scores did not correlate with biopsy Ishak histologic activity index and fibrosis scores (p=0.4, p=0.3). FIB4 scores were in correlation with biopsy Ishak HAI scores (p=0.03) but did not correlate with fibrosis scores (p=0.5). Conclusions: In our study, it was understood that 40% of the patients who had undergone biopsy were not able to start treatment, and some of these patients were recommended to be treated without the necessity of liver biopsy according to the guidelines. Fibrosis tests are insufficient to predict liver biopsy results. It is thought that they cannot help to reduce the need for liver biopsy.
Objectives: Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne zoonotic infection caused by Crimean Congo hemorrhagic fever virus (CCHFV). The aim of the present study was to investigate the association between blood neutrophilto-lymphocyte ratio (NLR) and mean platelet volume (MPV) which are simple markers of subclinical inflammation and CCHF. We also investigated the relationship of these markers with coagulation parameters. Methods: Thirty-one suspected CCHF patients, who submitted to Training and Research Hospital, Kayseri, Turkey between 2009 and 2013, were evaluated retrospectively. Among thirty-one patients, nineteen were laboratory confirmed CCHF patients diagnosed by RT-PCR or CCHFV-specific IgM positivity. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), creatinine phosphokinase (CK), coagulation parameters, white blood cell counts (WBCs), and platelet counts of patient group were compared with twenty-five healthy individuals. Results: MPV, AST, ALT, LDH, CK and coagulation parameters were significantly higher in patients with CCHF than the controls, whereas WBCs, neutrophil, lymphocyte, hemoglobin, platelet counts and NLR were significantly lower (p<0.05). We found no significant correlation between MPV, NLR and coagulation parameters. Conclusions: Our study demonstrates that MPV and NLR may be beneficial markers in the diagnosis of CCHF. But these parameters should not be considered stand-alone tests for this use owing to nonspecificity with other diseases.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.